Le Lézard
Classified in: Health
Subject: SHA

Members of Immunovia's Board of Directors purchase shares in the company


LUND, Sweden, May 4, 2021 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announced today that the following members of the Board of Directors have purchased shares in the company:

   

Member

  

Number of Shares

 

Total Investment                                   

                                   

Peter Høngaard Andersen

 

1,500

 

171,000 SEK                                        

                                   

Hans Johansson

 

1,700

 

192,100 SEK                                             

                                   

TOTAL

 

3,200

 

363,100 SEK                            

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMraytm. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMraytm PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final validation study was completed in Q1 2021. The accreditation process for Immunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial testing will begin in Q2 after the accreditation. The European launch plan will be communicated Q2 2021.

IMMraytm PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. The test will be exclusively provided by Immunovia Inc., Marlborough, Massachusetts, USA.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

CONTACT:

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: [email protected]
Tel: +46 73 376 76 64

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/members-of-immunovia-s-board-of-directors-purchase-shares-in-the-company,c3340062

The following files are available for download:

https://mb.cision.com/Main/13121/3340062/1412517.pdf

Press release (PDF)

 

SOURCE Immunovia AB


These press releases may also interest you

at 13:00
Mercy Grows, Enhances Mercy Personal Physicians Network with Blessing/Dedications at new Ellicott City and expanded Reisterstown sites in Spring 2024
As part of Mercy Health Services' ongoing efforts to expand the reach of the 149-year Sisters of Mercy tradition of quality health care, Mercy has officially opened Mercy Personal Physicians at Ellicott City and dedicated the newly expanded Mercy...

at 12:50
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
USA News Group ? A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as Johns Hopkins Medicine reports...

at 12:48
Healthcare Property Advisors Launches HPA Exchange LLC to Offer Healthcare Real Estate Investments to Individual Investors
Healthcare Property Advisors announced today the launch of HPA Exchange LLC, a new real estate investment sponsor that will provide accredited investors with private placement opportunities anchored by medical properties. The firm will initially...

at 12:39
International experts debate how to improve regulation of electronic cigarettes around the world
Dozens of experts debated how to improve the rules regarding electronic cigarettes, the consumption of which is a global reality, at the eighth edition of The E-Cigarette Summit, this Tuesday (14) in Washington DC, USA. Scientists, regulators,...

at 12:38
Denmark Pharmaceutical Market size is set to grow by USD 852.1 mn from 2024-2028, high investment in pharmaceutical industry to boost the market growth, Technavio
The global pharmaceutical market in Denmark size is estimated to grow by USD 852.1 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.63%  during the forecast period. ...

at 12:18
Parliamentary Secretary Drouin announces over $9.6 million to help the Canadian pork industry to prevent and prepare for a possible African swine fever outbreak
The Government of Canada is protecting the resilience of Canada's rural communities and the Canadian pork sector by supporting prevention and preparedness measures for African swine fever (ASF). ASF is a viral disease that only impacts pigs. While...

More news about Health...


News published on and distributed by: